$ACAD
ACADIA PHARMACEUTICALS INC

2013 Q3 Form 10-Q Financial Statement

#000119312513321550 Filed on August 06, 2013

View on sec.gov

Income Statement

Concept 2013 Q3 2013 Q2 2012 Q2
Revenue $240.0K $451.0K $599.0K
YoY Change -93.1% -24.71% 30.22%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.800M $2.500M $1.600M
YoY Change 153.33% 56.25% 60.0%
% of Gross Profit
Research & Development $7.254M $7.112M $4.472M
YoY Change 64.86% 59.03% 3.64%
% of Gross Profit
Depreciation & Amortization $40.00K $60.00K
YoY Change 33.33% 50.0%
% of Gross Profit
Operating Expenses $11.05M $9.608M $6.028M
YoY Change 87.78% 59.39% -14.42%
Operating Profit -$10.81M -$9.157M -$5.429M
YoY Change 349.15% 68.67% -17.54%
Interest Expense $116.0K $76.00K $10.00K
YoY Change 2220.0% 660.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$10.70M -$9.100M -$5.400M
YoY Change 345.83% 68.52% -18.18%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.70M -$9.081M -$5.419M
YoY Change 345.25% 67.58% -17.34%
Net Earnings / Revenue -4456.25% -2013.53% -904.67%
Basic Earnings Per Share
Diluted Earnings Per Share -$119.6K -$109.1K -$101.9K
COMMON SHARES
Basic Shares Outstanding 88.78M shares 79.16M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q3 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $196.2M $205.5M $21.30M
YoY Change 749.26% 864.56% -47.28%
Cash & Equivalents $11.80M $24.25M $9.208M
Short-Term Investments $184.4M $181.2M $12.10M
Other Short-Term Assets $2.500M $1.300M $400.0K
YoY Change 316.67% 225.0% -42.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $198.7M $206.8M $21.78M
YoY Change 738.82% 849.53% -46.89%
LONG-TERM ASSETS
Property, Plant & Equipment $490.0K $92.00K $92.00K
YoY Change 677.78% 0.0% -54.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $120.0K $56.00K $7.000K
YoY Change 5900.0% 700.0% -93.0%
Total Long-Term Assets $610.0K $148.0K $99.00K
YoY Change 838.46% 49.49% -67.0%
TOTAL ASSETS
Total Short-Term Assets $198.7M $206.8M $21.78M
Total Long-Term Assets $610.0K $148.0K $99.00K
Total Assets $199.3M $206.9M $21.87M
YoY Change 739.09% 845.91% -47.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.120M $1.177M $757.0K
YoY Change -0.97% 55.48% -31.18%
Accrued Expenses $6.670M $6.488M $5.225M
YoY Change 42.34% 24.17% 30.63%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $7.870M $7.776M $6.760M
YoY Change 29.31% 15.03% 14.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.70M $17.70M $2.400M
YoY Change 637.5% -4.0%
Total Long-Term Liabilities $2.000K $17.70M $2.400M
YoY Change 637.5% -4.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.870M $7.776M $6.760M
Total Long-Term Liabilities $2.000K $17.70M $2.400M
Total Liabilities $7.872M $25.40M $9.166M
YoY Change 29.35% 177.11% 7.84%
SHAREHOLDERS EQUITY
Retained Earnings -$393.6M -$382.9M -$358.5M
YoY Change 9.06% 6.81%
Common Stock $9.000K $8.000K $5.000K
YoY Change 50.0% 60.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $180.8M $181.5M $12.71M
YoY Change
Total Liabilities & Shareholders Equity $199.3M $206.9M $21.87M
YoY Change 739.09% 845.91% -47.04%

Cashflow Statement

Concept 2013 Q3 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income -$10.70M -$9.081M -$5.419M
YoY Change 345.25% 67.58% -17.34%
Depreciation, Depletion And Amortization $40.00K $60.00K
YoY Change 33.33% 50.0%
Cash From Operating Activities -$9.470M -$5.440M -$4.800M
YoY Change 78.34% 13.33% -9.09%
INVESTING ACTIVITIES
Capital Expenditures -$430.0K -$60.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$3.520M -$98.55M $8.390M
YoY Change 28.47% -1274.61% 30.48%
Cash From Investing Activities -$3.950M -$98.61M $8.390M
YoY Change 44.16% -1275.33% 30.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $107.9M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 970.0K 109.9M 60.00K
YoY Change -85.86% 183016.67% 20.0%
NET CHANGE
Cash From Operating Activities -9.470M -5.440M -4.800M
Cash From Investing Activities -3.950M -98.61M 8.390M
Cash From Financing Activities 970.0K 109.9M 60.00K
Net Change In Cash -12.45M 5.820M 3.650M
YoY Change 946.22% 59.45% 204.17%
FREE CASH FLOW
Cash From Operating Activities -$9.470M -$5.440M -$4.800M
Capital Expenditures -$430.0K -$60.00K
Free Cash Flow -$9.040M -$5.380M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
88783766 shares
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9208000
CY2013Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
5347137 shares
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83429819 shares
CY2013Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2013Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2013Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2013Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
5347137 shares
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83429819 shares
CY2013Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7776000
CY2013Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-26000
CY2013Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
913000
CY2013Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
81000
CY2013Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
564417000
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1177000
CY2013Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
339000
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
181475000
CY2013Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-382924000
CY2013Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
111000
CY2013Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q2 us-gaap Temporary Equity Redemption Value
TemporaryEquityRedemptionValue
17658000
CY2013Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6488000
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
8000
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
206909000
CY2013Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
56000
CY2013Q2 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
197941000
CY2013Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
181204000
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92000
CY2013Q2 us-gaap Assets
Assets
206909000
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24247000
CY2013Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
197971000
CY2013Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
15000000
CY2013Q2 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
204633000
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1310000
CY2013Q2 us-gaap Assets Current
AssetsCurrent
206761000
CY2013Q2 acad Accrued Clinical Development Services
AccruedClinicalDevelopmentServices
5155000
CY2013Q2 acad Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
78000
CY2013Q2 acad Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
108000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6889000
CY2012Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
5347137 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
73334216 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2012Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
5347137 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73334216 shares
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5948000
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
413000
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
146000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
452693000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1375000
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
364000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
84984000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-367720000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
434000
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Temporary Equity Redemption Value
TemporaryEquityRedemptionValue
17658000
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4139000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
108590000
CY2012Q4 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
56382000
CY2012Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
50068000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42000
CY2012Q4 us-gaap Assets
Assets
108590000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57899000
CY2012Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
56382000
CY2012Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
107598000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
581000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
108548000
CY2012Q4 acad Accrued Clinical Development Services
AccruedClinicalDevelopmentServices
3216000
CY2012Q4 acad Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
5000
CY2012Q4 acad Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
5000
dei Trading Symbol
TradingSymbol
ACAD
dei Entity Registrant Name
EntityRegistrantName
ACADIA PHARMACEUTICALS INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001070494
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12029000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
81105000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10854000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-30000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
56000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
162032000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
117000
us-gaap Revenues
Revenues
868000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
729000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15234000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-13000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15321000
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
63000
us-gaap Net Income Loss
NetIncomeLoss
-15204000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-473000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
110079000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4647000
us-gaap Share Based Compensation
ShareBasedCompensation
1646000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-33652000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-131702000
us-gaap Operating Expenses
OperatingExpenses
16189000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-323000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2349000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-198000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
110079000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
30393000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11542000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10030000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52932000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11388000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-6000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-8000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
9838000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
23000
us-gaap Revenues
Revenues
1049000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-475000
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
19000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11643000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
44000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11660000
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
-103000
us-gaap Net Income Loss
NetIncomeLoss
-11637000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
156000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
79000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3216000
us-gaap Share Based Compensation
ShareBasedCompensation
891000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2319000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
12270000
us-gaap Operating Expenses
OperatingExpenses
12709000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-85000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1721000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1203000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
98000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
22005000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9493000
CY2013Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
9200000 shares
CY2013Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
107900000
CY2012 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5347137 shares
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52961000 shares
CY2012Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11833000 shares
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2012Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
CY2012Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
10000
CY2012Q2 us-gaap Revenues
Revenues
599000
CY2012Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5422000
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5429000
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-5419000
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1556000
CY2012Q2 us-gaap Share Based Compensation
ShareBasedCompensation
478000
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
6028000
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4472000
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
83410000 shares
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10942000 shares
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2013Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-41000
CY2013Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
76000
CY2013Q2 us-gaap Revenues
Revenues
451000
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9122000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9157000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-9081000
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2496000
CY2013Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1100000
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
9608000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7112000

Files In Submission

Name View Source Status
0001193125-13-321550-index-headers.html Edgar Link pending
0001193125-13-321550-index.html Edgar Link pending
0001193125-13-321550.txt Edgar Link pending
0001193125-13-321550-xbrl.zip Edgar Link pending
acad-20130630.xml Edgar Link completed
acad-20130630.xsd Edgar Link pending
acad-20130630_cal.xml Edgar Link unprocessable
acad-20130630_def.xml Edgar Link unprocessable
acad-20130630_lab.xml Edgar Link unprocessable
acad-20130630_pre.xml Edgar Link unprocessable
d557868d10q.htm Edgar Link pending
d557868dex101.htm Edgar Link pending
d557868dex311.htm Edgar Link pending
d557868dex312.htm Edgar Link pending
d557868dex321.htm Edgar Link pending
d557868dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R28.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R29.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R30.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R31.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R32.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R33.xml Edgar Link unprocessable
R34.htm Edgar Link pending
R34.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending